Home » FDA Approves ImClone Systems’ New State-of-the-Art Manufacturing Facility
FDA Approves ImClone Systems’ New State-of-the-Art Manufacturing Facility
ImClone Systems Incorporated, a leader in the development and commercialization of novel cancer therapeutics, announced that it has received approval from the Food and Drug Administration for a second facility to manufacture Erbitux.
Imclone
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May